Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
KYMR Stock Chart & Stats
$64.63
-$0.34(-0.84%)
At close: 4:00 PM EST
$64.63
-$0.34(-0.84%)
Day’s Range― - ―
52-Week Range$19.45 - $68.46
Previous CloseN/A
Volume48.51K
Average Volume (3M)696.74K
Market Cap
$4.66B
Enterprise Value$4.52B
Total Cash (Recent Filing)$505.68M
Total Debt (Recent Filing)$84.00M
Price to Earnings (P/E)―
Beta2.23
Next Earnings
Feb 19, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.94
Shares Outstanding71,949,030
10 Day Avg. Volume756,169
30 Day Avg. Volume696,737
Financial Highlights & Ratios
PEG Ratio-0.74
Price to Book (P/B)3.61
Price to Sales (P/S)64.14
P/FCF Ratio-14.56
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue103.34
Enterprise Value/Gross Profit-139.30
Enterprise Value/Ebitda-15.81
Forecast
1Y Price Target
$73.22Price Target Upside13.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)-3.47
Revenue Forecast (FY)$58.20M
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsThe upcoming data readout for KT-621 in atopic dermatitis is expected to show its potential as a competitive alternative to Dupixent.
Financial PositionEnd of Q3 cash of $979MM is expected to provide runway into the second half of 2028.
Market PotentialThere is potential for significant long-term upside if KYMR's treatment proves to be an effective oral alternative to a drug forecasted to sell over $20 billion.
Bears Say
Data Interpretation ChallengesThe company cautions that small numbers and the lack of a placebo group in the Ph1b trial will make the data more difficult to interpret.
Trial Design ConcernsThe small, open-label design of the phase 1b study adds risk to interpreting the efficacy signal.
Valuation RisksInvestors are concerned that KYMR's high valuation is currently supported by only positive phase 1a results, requiring flawless upcoming phase 1b data.
Kymera Therapeutics News
KYMR FAQ
What was Kymera Therapeutics’s price range in the past 12 months?
Kymera Therapeutics lowest stock price was $19.45 and its highest was $68.45 in the past 12 months.
What is Kymera Therapeutics’s market cap?
Kymera Therapeutics’s market cap is $4.66B.
When is Kymera Therapeutics’s upcoming earnings report date?
Kymera Therapeutics’s upcoming earnings report date is Feb 19, 2026 which is in 89 days.
How were Kymera Therapeutics’s earnings last quarter?
Kymera Therapeutics released its earnings results on Nov 04, 2025. The company reported -$0.94 earnings per share for the quarter, missing the consensus estimate of -$0.77 by -$0.17.
Is Kymera Therapeutics overvalued?
According to Wall Street analysts Kymera Therapeutics’s price is currently Undervalued.
Does Kymera Therapeutics pay dividends?
Kymera Therapeutics does not currently pay dividends.
What is Kymera Therapeutics’s EPS estimate?
Kymera Therapeutics’s EPS estimate is -0.82.
How many shares outstanding does Kymera Therapeutics have?
Kymera Therapeutics has 71,949,030 shares outstanding.
What happened to Kymera Therapeutics’s price movement after its last earnings report?
Kymera Therapeutics reported an EPS of -$0.94 in its last earnings report, missing expectations of -$0.77. Following the earnings report the stock price went up 0.318%.
Which hedge fund is a major shareholder of Kymera Therapeutics?
Currently, no hedge funds are holding shares in KYMR
Kymera Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$73.22 (13.29% Upside)
$73.22 (13.29% Upside)
Blogger Sentiment
Bullish
KYMR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 33.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.30%
12-Months-Change
Fundamentals
Return on Equity
-32.09%
Trailing 12-Months
Asset Growth
6.49%
Trailing 12-Months
Company Description
Kymera Therapeutics
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
KYMR Company Deck
KYMR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Kymera Therapeutics reported a successful quarter with notable advancements in its STAT6 and IRF5 programs and strategic partnerships. The financial position remains strong, with a clear path forward for its pipeline. However, concerns about high expenses and data limitations from the Phase Ib trial, along with the challenge of placebo effects in trials, present areas of caution.View all KYMR earnings summariesKYMR Stock 12 Month Forecast
Average Price Target
$73.22
▲(13.29% Upside)
Technical Analysis
Protagonist Therapeutics
―
Apellis Pharmaceuticals
―
Crinetics Pharmaceuticals
―
Akero Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
11.73% Insiders
31.69% Mutual Funds
17.44% Other Institutional Investors
26.25% Public Companies and
Individual Investors